Description
CD22 CHO Recombinant Cell Line (Medium Expression) | 79557-M | Gentaur US, UK & Europe Disrtribition
Category: Immunotherapy/Cell Line
Application: Useful for screening and validating antibodies against CD22 and different CD22 CAR-T for immunotherapy research and drug discovery. Also useful for CD22 binding assays to screen for CD22 ligands.
Background: CD22, also known as Siglec-2, is expressed on the membrane of B-cells. It is reported to act as an inhibitory co-receptor of the B-cell receptor to control the body's B-cell response. In 2017 the FDA approved inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate targeting CD22, for patients with B-cell acute lymphoblastic leukemia (ALL). Additional therapies targeting CD22 are under evaluation.
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD22 protein (Genbank #NM_001771). Surface expression of CD22 was confirmed by flow cytometry. This clonal cell line was selected for medium level expression of CD22. A clone exhibiting higher levels of CD22 expression is also available (#79557-H). Please contact BPS Bioscience for additional information.
Product Type: Cell line
Shippement Condition: -80°C
